Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Blood advances·2026
Same author

Primary Cutaneous Anaplastic Large Cell Lymphoma: A Review of Diagnosis and Treatment for the General Oncologist.

Cancers·2026
Same author

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

HemaSphere·2026
Same author

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Molecular Genetic Demonstration of the Evolution of Transformed Mycosis Fungoides: A Clinicopathological and Molecular Case Study.

Journal of cutaneous pathology·2026

Related Experiment Video

Updated: Aug 26, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.8K

Circulating Tumor DNA in Lymphoma.

Swetha Kambhampati Thiruvengadam1, Jasmine Zain2

  • 1City of Hope National Medical Center, Duarte, CA, USA. sthiruvengadam@coh.org.

Current Hematologic Malignancy Reports
|October 10, 2022
PubMed
Summary
This summary is machine-generated.

Circulating tumor DNA (ctDNA) offers a minimally invasive method for detecting lymphoma. This blood-based biomarker aids in diagnosis, treatment monitoring, and predicting outcomes across various lymphoma subtypes.

Keywords:
Digital polymerase chain reactionLymphomaNext-generation sequencingctDNA

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.2K

Related Experiment Videos

Last Updated: Aug 26, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.8K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.2K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Hematology

Background:

  • Circulating tumor DNA (ctDNA) analysis represents a significant advancement in non-invasive cancer detection.
  • ctDNA, derived from tumor cells, can be identified in the blood of lymphoma patients.

Purpose of the Study:

  • To review current methods for ctDNA detection in lymphomas.
  • To discuss the clinical applications of ctDNA across diverse lymphoma subtypes.

Main Methods:

  • Review of ctDNA detection techniques including digital PCR and next-generation sequencing (NGS).
  • NGS methods discussed include VDJ sequencing, somatic mutation sequencing, and deep sequencing (CPPdS).

Main Results:

  • ctDNA aids in genotyping, disease classification, treatment response monitoring, and minimal residual disease (MRD) detection.
  • Applications span diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, Hodgkin's lymphoma, and others.
  • ctDNA can predict relapse and survival, even detecting MRD without radiographic evidence.

Conclusions:

  • ctDNA is an emerging biomarker for lymphoma, offering genotypic insights and prognostic information.
  • Standardization and clinical translation are crucial for widespread adoption in lymphoma management.
  • Further research is needed to fully integrate ctDNA into routine clinical practice.